Molecular MR Imaging of Prostate Cancer

This review summarizes recent developments regarding molecular imaging markers for magnetic resonance imaging (MRI) of prostate cancer (PCa). Currently, the clinical standard includes MR imaging using unspecific gadolinium-based contrast agents. Specific molecular probes for the diagnosis of PCa cou...

Descripción completa

Detalles Bibliográficos
Autores principales: Kader, Avan, Brangsch, Julia, Kaufmann, Jan O., Zhao, Jing, Mangarova, Dilyana B., Moeckel, Jana, Adams, Lisa C., Sack, Ingolf, Taupitz, Matthias, Hamm, Bernd, Makowski, Marcus R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7822017/
https://www.ncbi.nlm.nih.gov/pubmed/33375045
http://dx.doi.org/10.3390/biomedicines9010001
Descripción
Sumario:This review summarizes recent developments regarding molecular imaging markers for magnetic resonance imaging (MRI) of prostate cancer (PCa). Currently, the clinical standard includes MR imaging using unspecific gadolinium-based contrast agents. Specific molecular probes for the diagnosis of PCa could improve the molecular characterization of the tumor in a non-invasive examination. Furthermore, molecular probes could enable targeted therapies to suppress tumor growth or reduce the tumor size.

Ejemplares similares